Drug combination for recurrent brain tumors in children
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must have a brain or spinal tumor such as medulloblastoma, ependymoma, ATRT, or another rare type that has come back or grown after treatment.
- The child must be under 20 years old at the time of the original diagnosis.
- The child must be in reasonably good health, with adequate organ and blood cell counts (some low counts are allowed with adjusted dosing).
- The child must be physically able to walk or play at least moderately (Karnofsky score ≥50 or equivalent for younger children).
- The child must not have certain conditions like active infections, pregnancy, or significant heart or stomach problems that could make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.